Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line
- Authors:
- Published online on: November 25, 2020 https://doi.org/10.3892/mco.2020.2175
- Article Number: 13
-
Copyright: © Nakano et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Clinical evidence regarding eribulin treatment for patients with soft tissue sarcoma (STS) is limited to those with L‑sarcoma (leiomyosarcoma and liposarcoma) who have completed at least two chemotherapies. Whether histological subtypes and treatment lines affect the efficacy and safety of eribulin for patients with STS has yet to be elucidated. The current study retrospectively reviewed patients with STS receiving eribulin at the Cancer Institute Hospital of JFCR and evaluated the prognostic factors affecting its efficacy and safety by histological diagnoses and treatment lines. A total of 41 patients with STS, including 26 with L‑sarcoma, underwent eribulin treatment. Additionally, a total of and 14 patients, including 12 with L‑sarcoma, received eribulin as a second‑line treatment. The results revealed that patients with L‑sarcoma demonstrated longer progression‑free survival (PFS) rates compared with patients without L‑sarcoma (4.5 vs. 2.3 months; P=0.005). Furthermore, differences in treatment line significantly affected PFS (4.5 months in second‑line treatment vs. 2.4 months in later lines; P=0.037). A high number of patients with L‑sarcoma received eribulin as a second‑line treatment. Regarding safety, several adverse events were reported, such as neutropenia, which were more frequently observed in patients with L‑sarcoma or other patients receiving eribulin as a second‑line treatment. However, most adverse events were tolerable. The clinical efficacy of eribulin was increased in patients with L‑sarcoma, which was similar to previous clinical trials. However, treatment lines could also affect its efficacy. When evaluating the clinical value of eribulin to STS, it is important to consider treatment lines.
